|
Biological Activity:
An oral tyrosine kinase inhibitor (TKI), targeting FLT3 (FMS-Like Tyrosine kinase-3), c-KIT and PDGFR, thereby inhibiting cellular proliferation and inducing apoptosis.
References: online 1, 2, 3, 4, 5
L Kelly et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell , 2003, 1(5), 421 - 432. [online abstract]
IJ Griswold et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood 2004, 104(9), 2912-8. [online abstract]
Chemical Name: 1-piperazinecarboxamide, 4-[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]-
|